Funds holding Xilio Therapeutics Inc
ISIN US98422T2096 · United States
- Fund holders
- 3
- Of which ETFs
- 0 3 other funds
- Value held
- 1M $
- Share of capital
- 2.1 % of 5.8M shares on Mar 18, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 58,910 | 495.4K $ | 0.00 % | 1.02 % | as of Mar 31, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 51,695 | 434.8K $ | 0.89 % | as of Mar 31, 2026 ↗ | |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 13,055 | 109.8K $ | 0.00 % | 0.23 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Institutional managers
20 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | 5.6M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 422,505 | 3.6M $ | as of Mar 31, 2026 |
| Sio Capital Management, LLC | 152,464 | 1.3M $ | as of Mar 31, 2026 |
| Caligan Partners LP | 112,128 | 943K $ | as of Mar 31, 2026 |
| Merck & Co., Inc. | 105,982 | 891.3K $ | as of Mar 31, 2026 |
| Stonepine Capital Management, LLC | 64,162 | 539.6K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 57,493 | 483.5K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 49,566 | 416.9K $ | as of Mar 31, 2026 |
| AJU IB Investment Co., Ltd. | 47,695 | 401.1K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 37,197 | 312.8K $ | as of Mar 31, 2026 |
| FMR LLC | 36,558 | 307.5K $ | as of Mar 31, 2026 |
| GSA CAPITAL PARTNERS LLP | 16,946 | 143 $ | as of Mar 31, 2026 |
| Velan Capital Investment Management LP | 14,285 | 120.1K $ | as of Mar 31, 2026 |
| Ghisallo Capital Management LLC | 13,800 | 116.1K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 13,311 | 111.9K $ | as of Mar 31, 2026 |
| CWM, LLC | 4,206 | 35.4K $ | as of Mar 31, 2026 |
| UBS Group AG | 4,038 | 34K $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 240 | 2K $ | as of Mar 31, 2026 |
| ROYAL BANK OF CANADA | 91 | 1K $ | as of Mar 31, 2026 |
| Key Financial Inc | 59 | 496 $ | as of Mar 31, 2026 |
Declared shareholders of Xilio Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| BCLS II Equity Opportunities, LP and 2 others | 9.99 % | 664,021 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Xilio Therapeutics Inc". https://titelia.com/en/stocks/xilio-therapeutics-inc-US98422T2096